Patents Examined by Ian Dang
  • Patent number: 8835394
    Abstract: The present invention provides a method of treating basal cell carcinoma in a subject. Generally, the method includes administering to the subject an amount of IRM compound effective for treating basal cell carcinoma in a treatment cycle that includes at least two consecutive days in which the IRM compound is administered and at least one day in which the IRM compound is not administered.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: September 16, 2014
    Assignee: Medicis Pharmaceutical Corporation
    Inventors: Mary L. Owens, Terrance L. Fox, Angela M. Ginkel
  • Patent number: 8748375
    Abstract: Methods for affecting body composition include the use of amylin agonists, such as pramlintide or davalintide. Total body weight may be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: June 10, 2014
    Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Christine M. Mack, Jonathan David Roth
  • Patent number: 8748383
    Abstract: Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: June 10, 2014
    Assignees: Novartis AG, Emisphere Technologies, Inc.
    Inventors: Shoufeng Li, Anasuya Ashok Ghosh, Simon D. Bateman, Moise Azria, Alan E. Royce
  • Patent number: 8741839
    Abstract: Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization.
    Type: Grant
    Filed: January 18, 2010
    Date of Patent: June 3, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jennifer R. Cochran, Adam Silverman, Douglas Jones, Niv Papo
  • Patent number: 8729018
    Abstract: The present invention provides therapeutic agents and compositions comprising elastic peptides and therapeutic proteins. Such peptides exhibit a flexible, extended conformation. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist (e.g., GLP-1, exendin), insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: May 20, 2014
    Assignee: Duke University
    Inventor: Ashutosh Chilkoti
  • Patent number: 8722041
    Abstract: This invention provides monoclonal antibodies that recognize hENT1. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and/or prophylactic in disorders associated with aberrant hENT1 expression and/or activity.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: May 13, 2014
    Assignee: Governors of the University of Alberta
    Inventors: Marit L. Sandvold, Finn Myhren, Carol E. Cass, James D. Young
  • Patent number: 8716221
    Abstract: The present invention discloses a modified exendin or pharmaceutically acceptable salts thereof, wherein the modified exendin comprises an amino acid sequence having at least 90% sequence identity to SEQ ID No. 17 and the amino acid sequence has a higher stability than the non-modified exendin of SEQ ID No. 4. These compounds are useful in treating type 2 diabetes as GLP-1 receptor agonists.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: May 6, 2014
    Assignee: Wuxi Grandchamp Pharmaceutical Technology Co., Ltd.
    Inventors: Aifeng Lv, Changan Sun, Yali Wang
  • Patent number: 8715718
    Abstract: Compositions, methods, and kits for repair and production of extracellular matrix are provided. In the broad aspect, the composition comprises a ligand of ?5?1 integrin attached to a surface of a nanoparticle composed of a protein, with a proviso that the protein is not fibronectin.
    Type: Grant
    Filed: July 11, 2007
    Date of Patent: May 6, 2014
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Prabhas V. Moghe, Ram Sharma, Marian Pereira Guelakis
  • Patent number: 8680051
    Abstract: A composition for the prevention or treatment of type I diabetes in a subject, said composition comprising a GABAergic and incretin exemplified by GABA and GLP-1/Ex4. These are optionally provided together in a single composition to promote beta-cell regeneration prevent beta-cell apoptosis and control autoimmunity for the prevention and treatment of T1D in mammals.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: March 25, 2014
    Inventors: Qinghua Wang, Soltani Nepton
  • Patent number: 8680050
    Abstract: The present invention relates to compositions comprising growth hormone linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in administration to animals.
    Type: Grant
    Filed: August 2, 2010
    Date of Patent: March 25, 2014
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-Wei Wang, Nathan Geething, Jeffrey L. Cleland
  • Patent number: 8647866
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: February 11, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
  • Patent number: 8642542
    Abstract: The invention describes albumin fusion proteins comprising growth hormone and serum albumin. The invention also describes nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acid molecules, host cells transformed with these vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally, the invention describes compositions comprising the albumin fusion proteins, and methods of treating patients in need of growth hormone, comprising administering the albumin fusion proteins of the invention.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: February 4, 2014
    Assignee: Novozymes Biopharma DK A/S
    Inventor: David James Ballance
  • Patent number: 8637642
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: January 28, 2014
    Assignees: Seattle Genetics, Inc., Agensys, Inc.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An
  • Patent number: 8632979
    Abstract: The present invention provides methods for determining a putative agent that treats or prevent obesity and/or obesity related diseases comprising contacting cells with the putative agent and measuring the activity and/or level of Maf1 and/or the activity and/or level of KIAA1875. The present invention also provides the agent identified by the methods herein and methods of treating or preventing obesity and/or obesity related diseases in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits or downregulates Maf1 and/or activates or upregulates KIAA1875.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: January 21, 2014
    Assignees: Albert Einstein College of Medicine of Yeshiva University, University of Lausanne
    Inventors: Ian M. Willis, Nouria Hernandez, Wassim Hodroj
  • Patent number: 8614185
    Abstract: The present invention relates to melanocortin receptor binding conjugates and methods of making and using the foregoing.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: December 24, 2013
    Assignee: Centocor Ortho Biotech Inc.
    Inventor: George Heavner
  • Patent number: 8603987
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: December 10, 2013
    Assignee: Galaxy Biotech, LLC
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
  • Patent number: 8603973
    Abstract: The present invention provides a recombinant fusion protein which stimulates the rejuvenation and reactivation of skin and epidermal cells for improving skin appearance, smoothing wrinkles and freckles, and whitening skin. Particularly, the present invention provides various types of products for improving skin, which contain recombinant fusion protein of human serum albumin (HSA) with cytokine peptides (EGF, FGF, KGF, HGH, HGF, PDGF, GCSF, interferon, IL-11 or IGF) by genetic engineering technology. The fusion protein can be used independently or in a combination or combination with yeast fermentation products, or with varied emulsifiers, thickeners, moisturizer, preservatives, yeasts and ferments.
    Type: Grant
    Filed: September 24, 2008
    Date of Patent: December 10, 2013
    Assignees: Tianjin Sinobiotech Ltd., Fortunerock, Inc. USA
    Inventors: Yan Fu, Zailin Yu
  • Patent number: 8568706
    Abstract: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.
    Type: Grant
    Filed: November 2, 2009
    Date of Patent: October 29, 2013
    Assignee: Allozyne, Inc.
    Inventors: Kenneth H. Grabstein, Aijun Wang, Natalie Winblade Nairn, Thomas James Graddis, Stephen McCraith, Deepshikha Datta
  • Patent number: 8536121
    Abstract: The present invention provides the use of ?arrestin2 protein or its up-regulators for manufacturing a composition for the prevention or treatment of insulin resistance or related disease in mammals. The reagents and the kits for the specific identification of ?arrestin2 protein or its coding gene or transcript are also provided which can be used in diagnosis of insulin resistance or related diseases.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: September 17, 2013
    Assignee: Shanghai Institutes for Biological Sciences, CAS
    Inventors: Gang Pei, Bing Luan, Jian Zhao
  • Patent number: 8530428
    Abstract: Methods for treating cancer (e.g., metastatic cancer to the lung or chronic lymphocytic leukemia) in patients are described that include administrating an aerosolized granulocyte macrophage colony stimulating factor to the patients. Methods for stimulating an immune response in patients also are described.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: September 10, 2013
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Svetomir N. Markovic